# Isomorphic Labs lands $5 billion as AI drug discovery moves from promise to proof

Published 2026-11-17T14:54:55+00:00 · Updated 2026-11-17T18:25:42+00:00 · By superintelligencenews@gmail.com
Canonical: https://superintelligencenews.com/ai-fields/ai-drug-discovery-5b-isomorphic-labs/

> Isomorphic Labs has raised $5 billion to push its AI drug candidates toward clinical trials, with the new reporting adding that Demis Hassabis has shifted focus to the company and that the AlphaFold team behind it earned the Nobel Prize in chemistry.

## Key facts

- Isomorphic Labs raised $5 billion in a Series C funding round, TechCrunch reported on 2026-11-17.
- The company was spun out of DeepMind in 2021 and builds on AlphaFold-related work.
- TechCrunch said Isomorphic Labs previously raised $2.1 billion in a Series B in May.
- BW Businessworld said the first AI-designed drugs are expected in clinical trials by the end of 2026.
- TechCrunch said the round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz as a new investor.

**Update — November 17, 2026 6:25 pm**

TechCrunch added that the new round comes after founder Demis Hassabis stepped away from his day-to-day role leading DeepMind to focus on Isomorphic Labs, while remaining chairman of DeepMind.

The report also says Hassabis and former DeepMind director John Jumper won the Nobel Prize in chemistry for the AlphaFold work that underpins the company’s drug-discovery platform.

 

Isomorphic Labs has raised $5 billion in a Series C funding round to push its AI-designed drug candidates toward clinical trials, according to TechCrunch. The deal gives the DeepMind spinout the capital to expand its drug-design engine and test whether model-driven discovery can consistently produce medicines that hold up in human studies.

 

## What happened

 

TechCrunch reported on 2026-11-17 that the round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor. Existing backers also participated, including GV, Capital G, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund.

 

The company said the proceeds will go toward advancing its drug-design engine and broadening the range of medicine types it can tackle. The central goal, according to the report, is to move drug candidates into clinical trials.

 

That is a significant step up from the earlier phase of AI drug discovery, where the main claim is usually speed and better candidate selection. Clinical trials are where those claims meet the hard realities of safety, efficacy and manufacturability.

 

## Why it matters

 

This is not just another large venture round. It is a scale test for one of the most closely watched applications of artificial intelligence: drug discovery.

 

Isomorphic Labs is trying to turn AI from a research advantage into a repeatable industrial process. If it succeeds, the company could reduce the time and cost of early-stage drug design, improve the odds of finding viable molecules, and reshape how pharma partners build pipelines. If it stumbles, the round will still stand as a reminder that enormous capital does not automatically solve biology’s complexity.

 

The financing also matters because it shows that major investors still believe AI can produce durable value outside chatbots and consumer software. Drug discovery is a long-cycle, high-risk field with years of development before a product reaches patients. Capital of this size suggests investors are willing to wait for evidence.

 

## How did Isomorphic Labs get here?

 

Isomorphic Labs was spun out of DeepMind in 2021, building on work tied to AlphaFold, the protein-structure prediction system that became one of DeepMind’s most visible scientific advances. That lineage matters because it gives the company a scientific story that is more concrete than a generic AI pitch.

 

AI drug discovery aims to speed up molecule design and improve hit rates before expensive clinical testing begins. In practical terms, that means using machine learning systems to help identify promising compounds, filter weak candidates and guide chemists toward molecules more likely to succeed in the lab.

 

TechCrunch said the company has reported positive preclinical results in oncology and immunology, and that it has already formed partnerships with Eli Lilly, Novartis and Johnson & Johnson. Those relationships matter because they suggest the platform is not operating in isolation; it is being tested alongside some of the most established names in pharma.

 

### From DeepMind research to a commercial platform

 

That transition from research lab to commercial company is central to the Isomorphic story. A research breakthrough can be scientifically impressive without being commercially scalable. Isomorphic Labs is now being judged on whether it can do both.

 

According to CIOL, the company’s founder and CEO is Demis Hassabis, who also leads Google DeepMind. That dual role underscores how closely the venture remains tied to DeepMind’s scientific pedigree, even as it pursues a distinct business model.

 

## How big is this round compared with the last one?

 

The new funding dwarfs the company’s prior reported round. TechCrunch said Isomorphic Labs raised $2.1 billion in a Series B in May, while CIOL and BW Businessworld both described a $2.1 billion earlier round, with BW Businessworld specifying that it was led by Thrive Capital. The latest Series C is therefore more than twice the size of the previous financing, based on the reporting available.

 

There is one important caveat: TechCrunch said the new valuation was not disclosed, though Bloomberg had earlier reported a $50 billion target. That means investors and observers know how much capital was raised, but not exactly what price the market assigned to the company in this round.

 

| Milestone | Date | Detail |
| --- | --- | --- |
| Spinout from DeepMind | 2021 | Isomorphic Labs was formed from DeepMind’s drug-discovery work. |
| Series B | May | TechCrunch reported a $2.1 billion round. |
| Series C | 2026-11-17 | TechCrunch reported a $5 billion round co-led by Greenoaks and Sequoia Capital. |
| Clinical-trial target | End-2026 | BW Businessworld said the first AI-designed drugs are expected in trials by then. |

 

## Who is backing the company?

 

The investor list is notable for its breadth. Greenoaks and Sequoia Capital co-led the round, while Andreessen Horowitz came in as a new investor. Existing supporters who also took part included GV, Capital G, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund, according to TechCrunch.

 

That mix matters for two reasons. First, it shows continuing support from investors already comfortable with the company’s long development timeline. Second, it broadens the base of financial and strategic backing behind a platform that will likely need years of capital-intensive work before it can prove commercial return.

 

### Why the backers matter

 

For a company in drug discovery, investor confidence is not just about size. It is also about endurance. The path from computational design to approved medicine is slow, expensive and uncertain. A large syndicate can help Isomorphic Labs absorb that uncertainty while keeping pressure on its development program.

 

## What are the key scientific claims?

 

The company’s core claim is that its drug design engine works well enough to generate a repeatable process for creating new medicines. CIOL quoted Max Jaderberg, the company’s president, saying, “Our drug design engine works, and it's giving us a repeatable way to design new medicines”.

 

That is an ambitious assertion, and one that will only be fully tested as candidates move beyond preclinical work. In biotech, a platform can look highly effective in narrow settings and still struggle when faced with the complexity of human disease.

 

TechCrunch said the company has seen positive preclinical results in oncology and immunology. Those are among the most commercially significant and scientifically challenging therapeutic areas, which raises the stakes for what comes next.

 

## Background and context

 

Isomorphic Labs sits at the intersection of two powerful trends: the push to use AI in life sciences and the search for faster, cheaper ways to discover medicines. The company’s origin story gives it credibility in both camps.

 

AlphaFold, DeepMind’s protein-folding model, changed expectations for what AI could contribute to biology. It did not solve drug discovery on its own, but it demonstrated that machine learning could meaningfully advance a hard scientific problem once thought too complex for practical prediction. Isomorphic Labs is one of the clearest attempts to turn that success into a product and, eventually, a pipeline of actual drugs.

 

That is why the company’s partnerships with Eli Lilly, Novartis and Johnson & Johnson matter so much. These are not speculative alliances with no obvious path to market. They suggest the industry is willing to experiment with AI-assisted discovery at scale, while still relying on the traditional expertise of big pharma to carry candidates through development.

 

CIOL also reported that Ruth Porat, president and chief investment officer at Alphabet and Google, said, “The application of AI in healthcare offers a profound opportunity.” The quote captures the strategic logic behind the investment: health care is one of the few markets large enough to justify years of AI research, wet-lab validation and clinical testing.

 

## How does the reporting differ across outlets?

 

The broad outline is consistent across TechCrunch, CIOL and BW Businessworld, but there are a few differences worth noting.

 

- **TechCrunch** reported the $5 billion Series C, the co-leads, the new investor and the existing participants, and said the company aims to move drug candidates into clinical trials.
- **CIOL** focused on the same company and financing story, identifying Demis Hassabis as founder and CEO and emphasizing the scale of the opportunity in health care.
- **BW Businessworld** added a timing claim, saying the first AI-designed drugs are expected in clinical trials by the end of 2026, later than a prior late-2025 target.

 

One other point of divergence concerns the earlier round. TechCrunch described the prior financing as a $2.1 billion Series B in May. CIOL and BW Businessworld also cited a $2.1 billion round, with BW Businessworld adding that it was Thrive-led. The figure is consistent, though the sourcing language differs.

 

## By the numbers

 

The company’s financing history is now large enough to stand on its own as a data point in the AI sector.

 

| Figure | What it refers to | Source |
| --- | --- | --- |
| $5 billion | Series C funding | TechCrunch |
| $2.1 billion | Previous round reported in May | TechCrunch |
| 2021 | Year Isomorphic Labs spun out of DeepMind | TechCrunch |
| 2026 | Expected timing for first AI-designed drugs entering clinical trials | BW Businessworld |
| $50 billion | Bloomberg-reported valuation target mentioned by TechCrunch | TechCrunch |

 

## What happens next?

 

The next phase is execution. The most important open question is whether Isomorphic Labs can convert computational promise into clinical candidates that advance on schedule. BW Businessworld said the first AI-designed drugs are expected in trials by the end of 2026, which gives the company a concrete near-term milestone to hit.

 

Several questions remain unresolved:

 

- What valuation, if any, was assigned in the Series C?
- Which drug candidates will be first to enter clinical trials?
- How much of the new capital is earmarked for partnered programs versus internal ones?
- Whether the earlier $2.1 billion figure reflected the same round in different reporting, or a separate prior raise, will also remain a point of scrutiny until the company or its investors clarify the funding history.

 

Those details will matter because the market has moved beyond asking whether AI can assist biology. The real question now is whether a platform like Isomorphic Labs can become a reliable source of medicines, not just promising models.

 

## The bigger test for AI drug discovery

 

This round is a vote of confidence, but it is also a deadline of sorts. The amount of money is large enough to raise expectations and the scientific pedigree is strong enough to draw attention. What remains is the hardest part: proving that the engine can produce real drugs that survive the long road from design to patient.

 

If the company reaches clinical trials with credible candidates, it will strengthen the case that AI can change the economics of early drug development. If not, the funding will still stand as evidence of how much faith investors had in a technology that remains unproven at full scale.

## Frequently asked questions

### What is Isomorphic Labs?

Isomorphic Labs is a drug-discovery company spun out of DeepMind in 2021. It uses AI to design and evaluate potential medicines, building on scientific work related to AlphaFold and partnerships with major pharmaceutical companies.

### How much funding did Isomorphic Labs raise?

Isomorphic Labs raised $5 billion in a Series C funding round, according to TechCrunch. The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor.

### Why is this funding round important?

This funding round is important because it is a major test of whether AI can produce drug candidates that survive the step from preclinical design to clinical trials. It also signals continued investor belief in AI applications beyond consumer software.

### When could the first AI-designed drugs enter clinical trials?

BW Businessworld said the first AI-designed drugs are expected in clinical trials by the end of 2026. That timing is later than a prior late-2025 target, according to the same report.

## Sources

- [TechCrunch](https://techcrunch.com/2026/11/17/isomorphic-labs-raises-5b-as-it-looks-to-take-drug-candidates-to-clinical-trials/)
- [CIOL](https://www.ciol.com/funding-acquistion-merger/isomorphic-labs-raises-2-1-billion-ai-drug-discovery-11829709)
- [BW Businessworld](https://www.businessworld.in/article/isomorphic-labs-raises-2-1-bn-in-thrive-led-funding-to-scale-ai-drug-discovery-606525)
